Clinical trials: Gametocytes
Malaria
Combination Antimalarials in Uncomplicated Malaria
The purpose of this study is to study the efficacy of sulfadoxine-pyrimethamine on its own and compare this with efficacy of a new combination antimalarial therapy, either sulphadoxine-pyrimethamine plus artesunate or…
- Trial name
- NCT00203801
- Testing
- Sulfadoxine-pyrimethamine, Artesunate plus sulfadoxine-pyrimethamine, Artemether-lumefantrine
- Where
- 7 sites in Eswatini, Mozambique and 1 more
- Volunteers
- 700 people
- Sponsor
- University of Cape Town
Malaria
Malaria Transmission in Humans and Mosquitoes at the Area of Sabou, Burkina Faso
Background: Malaria is a disease that affects many people in Burkina Faso. It is caused by germs that are spread by mosquito bites. A vaccine that blocks the spread of malaria is important to get rid of the disease.
- Trial name
- NCT04650815
- Where
- 2 sites in Burkina Faso
- Volunteers
- 608 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria, Falciparum
Mass-Drug Administration to Reduce Malaria Transmission
In the 1950s, the WHO included mass drug administration (MDA) with antimalarial drugs as a tool for malaria control in 'exceptional conditions when conventional control strategies have failed'.
- Trial name
- MDATRANS (NCT00509015)
- Testing
- Sulphadoxine-pyrimethamine (day 1: 500mg S&25mg P/20 kg), Artesunate (day 1,2,3: 4 mg/kg), Primaquine-base (day 3: 0.75 mg/kg)
- Where
- Tanzania
- Volunteers
- 6,000 people
- Sponsor
- Radboud University Medical Center
Malaria
Preventing the Spread of Malaria in Mali
A vaccine which interrupts malaria transmission is a critical tool to achieve the ultimate goal of eradication of this disease. Transmission blocking vaccines work by inducing antibody in vaccinated individuals that inhibits the…
- Trial name
- NCT01360112
- Where
- Mali
- Volunteers
- 816 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)